Kentucky has one of the highest opioid overdose mortality rates in the United States. Accurate estimates of people with opioid use disorder (OUD) are critical to plan for the scope of interventions ...required to reduce overdose and opioid misuse. Commonly used household surveys are known to underestimate OUD at the state-level and do not provide county-level estimates.
We performed a multi-sample capture-recapture analysis to estimate OUD prevalence in Kentucky in 2018 and 2019. We utilized four statewide datasets that were linked at the individual level: 1) Registry of Vital Statistics, 2) Emergency Medical Services (EMS), 3) Kentucky’s Prescription Drug Monitoring Program (PDMP), and 4) Kentucky Medicaid. We included persons aged 18–64 years who resided in Kentucky between 2018 and 2019. We identified individuals with administrative data consistent with OUD in each of the datasets, including a fatal opioid-involved overdose (Vital Statistics), EMS runs for suspected opioid overdose, receipt of buprenorphine for OUD treatment (PDMP), or Medicaid claims for OUD. Observed and estimated counts of OUD cases and prevalence of OUD among the adult population in Kentucky.
The estimated statewide OUD prevalence was 5.5 % and 5.9 % for 2018 and 2019, respectively, ranging from 1.3 % to 17.7 % across Kentucky counties. As expected, counties with the highest OUD rates were Appalachian counties (eastern area) of the state.
Our analysis reveals a substantially larger proportion of KY residents have OUD than previously estimated. Our approach offers a model for states needing county-level estimates of OUD.
•We employed a capture-recapture method to estimate opioid use disorder prevalence in Kentucky.•Statewide OUD prevalence was 5.5 % and 5.9 % for 2018 and 2019, respectively, for adults 18–64 years.•County prevalence ranged from 1.3 % to 17.7 %.•Total estimated prevalence of OUD in Kentucky is nearly three times higher than previous estimates.
Since 2017, a total of 10 states have mandated naloxone coprescribing intended to prevent fatal opioid overdoses. This study aims to assess the association between naloxone coprescribing/offering ...mandates and opioid-involved overdose deaths on the basis of the opioid type.
Data on overdose deaths from 1999 to 2020 came from the National Center for Health Statistics CDC WONDER Online Database. This study examined deaths stratified by illicit/synthetic opioids and prescription/treatment opioids. Difference-in-difference negative binomial regression models estimated average marginal effects and 95% CIs. Covariates included opioid dispensing rate, Good Samaritan law, pharmacy-based naloxone access law, mandatory use of prescription drug monitoring program, and recreational cannabis dispensaries. Data collection and analysis were conducted in 2022.
Ten states implemented naloxone coprescribing/offering mandates during the period. Coprescribing/offering mandates significantly reduced the number of prescription/treatment overdose deaths by 8.61 per state per quarter (95% CI= –15.13, –2.09), a 16% reduction from the counterfactual estimates. Coprescribing/offering mandates did not significantly impact illicit/synthetic overdose deaths (average marginal effect=0.32; 95% CI= –18.27, 18.91).
Coprescribing/offering mandates prevent overdose deaths for its target population, individuals using prescription/treatment opioids. These mandates do not appear to impact populations using illicit/synthetic opioids; thus, expanded efforts are needed to reach these individuals.
•In 2017, approximately 17,000 patients in Florida were concurrently dispensed opioids, benzodiazepines, and carisoprodol.•“Holy Trinity” recipients were associated with top 1% prescribers in ...multiple drug classes and more multiple provider episodes.•In 2017, approximately one-half of the triple drug combinations were written by single, as opposed to multiple, prescribers.
High-risk combinations of controlled medications, such as those involving opioid analgesics, are under increased scrutiny because of their contribution to the opioid epidemic in the United States. Responsible prescribing guidelines indicate that the triple drug combination--opioids, benzodiazepines and skeletal muscle relaxants, especially carisoprodol--should not be concurrently prescribed.
This pharmacoepidemiologic study was designed to primarily examine the characteristics of patients receiving this triple combination compared to the group receiving only opioids and benzodiazepines.
Results show that, while the number of exposed patients has declined since 2012, approximately 17,000 Floridians were prescribed this combination in 2017 alone. Demographically, recipients of these prescriptions were younger, more likely to be female, and geographically-localized. Furthermore, these patients were more frequently associated with a prescriber in the top 1% of opioid and/or benzodiazepine prescribing, have more multiple provider episodes (“doctor shopping”), and receive higher mean daily opioid dosages.
These findings raise important questions as to how frequently prescribers are checking prescription drug monitoring programs, following US Centers for Disease Control and Prevention opioid prescribing guidelines, and/or handling the clinical challenges associated with pharmaceutical management of patients with complex, painful health conditions.
Abstract
Background
“Doctor shopping” typically refers to patients that seek controlled substance prescriptions from multiple providers with the presumed intent to obtain these medications for ...non-medical use and/or diversion. The purpose of this scoping review is to document and examine the criteria used to identify “doctor shopping” from dispensing data in the United States.
Methods
A scoping review was conducted on “doctor shopping” or analogous terminology from January 1, 2000, through December 31, 2020, using the Web of Science Core Collection (seven citation indexes). Our search was limited to the United States only, English-language, peer-reviewed and US federal government studies. Studies without explicit “doctor shopping” criteria were excluded. Key components of these criteria included the number of prescribers and dispensers, dispensing period, and drug class (e.g., opioids).
Results
Of 9,845 records identified, 95 articles met the inclusion criteria and our pool of studies ranged from years 2003 to 2020. The most common threshold-based or count definition was (≥4 Prescribers P AND ≥4 Dispensers D) (n = 12). Thirty-three studies used a 365-day detection window. Opioids alone were studied most commonly (n = 69), followed by benzodiazepines and stimulants (n = 5 and n = 2, respectively). Only 39 (41%) studies provided specific drug lists with active ingredients.
Conclusion
Relatively simple P x D criteria for identifying “doctor shopping” are still the dominant paradigm with the need for ongoing validation. The value of P x D criteria may change through time with more diverse methods applied to dispensing data emerging.
Objective. To examine the prevalence and duration of skeletal muscle relaxant (SMR) treatment among commercially insured adults in the United States. Methods. We used the MarketScan Research Database ...to identify a cohort of adults 18 to 64years who had greater than or equal to2-year continuous enrollment between 2005 and 2018. We estimated the prevalence of SMR treatment using a repeated cross-sectional design and derived treatment duration using the Kaplan-Meier method. Analyses were stratified by age group, sex, geographic region, individual SMR agent, and musculoskeletal disorder. Results. 48.7 million individuals were included. Treatment prevalence ranged from 61.5 to 68.3 per 1,000. About one-third of users did not have a preceding musculoskeletal disorder diagnosis. Cyclobenzaprine was the dominant agent accounting for >50% of prescriptions. The considerable growth in the use of baclofen, tizanidine, and methocarbamol paralleled with a decline in carisoprodol and metaxalone use. The prevalence was highest in the South while lowest in the Northeast. The median treatment duration was 14 days with 4.0%, 1.9%, and 1.0% of individuals using SMRs for more than 90, 180, and 365 days, respectively. Compared with cyclobenzaprine, patients initiating baclofen, tizanidine, and carisoprodol had longer treatment duration. Conclusions. SMRs are widely used in the United States. Their use slightly increased in recent years, but trends varied among individual agents, patient groups, and geographic regions. Despite limited evidence to support efficacy, a sizable number of U.S. adults used SMRs for long-term and off-label conditions. Further study is needed to understand determinants of treatment as well as outcomes associated with such use. Key Words: Baclofen; Chlorzoxazone; Cyclobenzaprine; Carisoprodol; Drug Utilization Study; Metaxalone; Methocarbamol; Musculoskeletal Pain; Orphenadrine; Prevalence; Skeletal Muscle Relaxants; Tizanidine; Treatment Duration
We present our open-source pipeline for quickly enhancing open data sets with research-focused expansions and show its effectiveness on a cornerstone open data set released by the Cook County ...government in Illinois. The City of Chicago and Cook County were both early adopters of open data portals and have made a wide variety of data available to the public; we focus on the medical examiner case archive which provides information about deaths recorded by Cook County’s Office of the Medical Examiner, including overdoses invaluable to substance use disorder research. Our pipeline derives key variables from open data and links to other publicly available data sets in support of accelerating translational research on substance use disorders. Our methods apply to location-based analyses of overdoses in general and, as an example, we highlight their impact on opioid research. We provide our pipeline as open-source software to act as open infrastructure for open data to help fill the gap between data release and data use.
•“Doctor or pharmacy shopping” for opioids has declined precipitously in the United States.•Common data-driven algorithms may inadvertently identify patients with cancer.•Multiple provider episodes ...may signal problems with care rather than opioid abuse.•Improved methods of monitoring multiple provider episodes are needed.
The term “doctor and pharmacy shopping” colloquially describes patients with high multiple provider episodes (MPEs)-a threshold count of distinct prescribers and/or pharmacies involved in prescription fulfillment. Opioid-related MPEs are implicated in the global opioid crisis and heavily monitored by government databases such as U.S. state prescription drug monitoring programs (PDMPs). We applied a widely-used MPE definition to examine U.S. trends from a large, commercially-insured population from 2010 to 2017. Further, we examined the proportion of enrollees identified as “doctor shoppers” with evidence of a cancer diagnosis to examine the risk of false positives.
Using a large, commercially-insured population, we identified patients with opioid-related MPEs: opioid prescriptions (Schedule II-V, no buprenorphine) filled from ≥5 prescribers AND ≥ 5 pharmacies within the past 90 days (“5x5x90d”). Quarterly rates per 100,000 enrollees (two specifications) were calculated between 2010 and 2017. We examined the trend in a recently published all-payer, 7 state cohort from the U.S. Centers for Disease Control and Prevention for comparison. Cancer-related ICD-9/10-CM codes were used.
Quarterly MPE rates declined by approximately 73 % from 18.2–4.9 per 100,000 enrollee population with controlled substance prescriptions. In 2017, nearly one fifth of these commercially-insured enrollees identified by the 5x5x90d algorithm were diagnosed with cancer. Approximately 8% of this sample included patients with ≥ 1 buprenorphine prescriptions.
Opioid “shopping” flags are a long-standing but rapidly fading PDMP signal. To avoid unintended consequences, such as identifying legitimate medical encounters requiring high healthcare utilization or opioid treatment, while maintaining vigilance, more nuanced and sophisticated approaches are needed.
•California’s updated PDMP added proactive reports and mandatory registration.•These features were associated with a short-term decrease in 3/7 prescribing outcomes.•Decreases in quantity and risky ...opioids prescribing ranged between 8% and 14 %.•Freqency and other high-risk opioid prescribing patterns remained unchanged.
: In 2016, California updated its prescription drug monitoring program (PDMP), adding two key features: automated proactive reports to prescribers and mandatory registration for prescribers and pharmacists. The effects of these changes on prescribing patterns have not yet been examined. We aimed to evaluate the joint effect of these two PDMP features on county-level prescribing practices in California.
: Using county-level quarterly data from 2012 to 2017, we estimated the absolute change associated with the implementation of these two PDMP features in seven prescribing indicators in California versus a control group comprising counties in Florida and Washington: opioid prescription rate per 1000 residents; patients’ mean daily opioid dosage in milligrams of morphine equivalentsMME; prescribers’ mean daily MME prescribed; prescribers’ mean number of opioid prescriptions per day; percentage of patients getting >90 MME/day; percentage of days with overlapping prescriptions for opioids and benzodiazepines; multiple opioid provider episodes per 100,000 residents.
: Proactive reports and mandatory registration were associated with a 7.7 MME decrease in patients’ mean daily opioid dose (95 %CI: -11.4, -2.9); a 1.8 decrease in the percentage of patients prescribed high-dose opioids (95 %CI: -2.3, -0.9); and a 6.3 MME decrease in prescribers’ mean daily dose prescribed (95 %CI: -10.0, -1.3).
: California’s implementation of these two PDMP features was associated with decreases in the total quantity of opioid MMEs prescribed, and indicators of patients prescribed high-dose opioids compared to states that had PDMP’s without these features. Rates of opioid prescribing and other high-risk prescribing patterns remained unchanged.
Consumption of licit and/or illicit compounds during sporting events has traditionally been monitored using population surveys, medical records, and law enforcement seizure data. This pilot study ...evaluated the temporal and geospatial patterns in drug consumption during a university football game from wastewater using liquid chromatography tandem mass spectrometry (LC-MS/MS). Untreated wastewater samples were collected from three locations within or near the same football stadium every 30 min during a university football game. This analysis leveraged two LCMS/ MS instruments (Waters Acquity TQD and a Shimadzu 8040) to analyze samples for 58 licit or illicit compounds and some of their metabolites. Bayesian multilevel models were implemented to estimate mass load and population-level drug consumption, while accounting for multiple instrument runs and concentrations censored at the lower limit of quantitation. Overall, 29 compounds were detected in at least one wastewater sample collected during the game. The 10 most common compounds included opioids, anorectics, stimulants, and decongestants. For compounds detected in more than 50% of samples, temporal trends in median mass load were correlated with the timing of the game; peak loads for cocaine and tramadol occurred during the first quarter of the game and for phentermine during the third quarter. Stadium-wide estimates of the number of doses of drugs consumed were rank ordered as follows: oxycodone (n = 3246) > hydrocodone (n = 2260) > phentermine (n = 513) > cocaine (n = 415) > amphetamine (n = 372) > tramadol (n = 360) > pseudoephedrine (n = 324). This analysis represents the most comprehensive assessment of drug consumption during a university football game and indicates that wastewater-based epidemiology has potential to inform public health interventions focused on reducing recreational drug consumption during large-scale sporting events.
Display omitted
•Estimates of population-level drug consumption during a college sporting event.•SPE-LC-MS/MS used to analyze wastewater for 58 compounds.•Bayesian multilevel model accounted for missing data and use of multiple instruments.
PDF
